Wai Yuen Tong Medicine Holdings's revenue for the
six
months ended in Sep. 2023 was HK$679 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was HK$1,359 Mil.
Wai Yuen Tong Medicine Holdings's Revenue per Share for the
six
months ended in Sep. 2023 was HK$0.57.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$1.14.
Warning Sign:
Wai Yuen Tong Medicine Holdings Ltd revenue growth has slowed down over the past 12 months.
During the past 13 years, Wai Yuen Tong Medicine Holdings's highest 3-Year average Revenue per Share Growth Rate was 46.90% per year. The lowest was -71.20% per year. And the median was -27.20% per year.
Wai Yuen Tong Medicine Holdings Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Wai Yuen Tong Medicine Holdings's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's Revenue falls into.
Wai Yuen Tong Medicine Holdings Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,359 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Yuen Tong Medicine Holdings (HKSE:00897) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Wai Yuen Tong Medicine Holdings Revenue Related Terms
Thank you for viewing the detailed overview of Wai Yuen Tong Medicine Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Wai Yuen Tong Medicine Holdings (HKSE:00897) Business Description
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties in the agricultural produce market. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:00897 has been successfully added to your 